Kiniksa Pharmaceuticals International, plc (KNSA)
| Market Cap | 6.20B +116.6% |
| Revenue (ttm) | 840.85M +58.9% |
| Net Income | 80.66M +1,583.9% |
| EPS | 0.99 +1,399.6% |
| Shares Out | 78.02M |
| PE Ratio | 79.95 |
| Forward PE | 55.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 575,764 |
| Open | 83.41 |
| Previous Close | 83.17 |
| Day's Range | 78.74 - 84.06 |
| 52-Week Range | 35.20 - 84.06 |
| Beta | 0.04 |
| Analysts | Strong Buy |
| Price Target | 98.00 (+23.31%) |
| Est. Earnings | Nov 3, 2026 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $98.0, which is an increase of 23.31% from the latest price.
News
Kiniksa Pharmaceuticals International, Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw record revenue growth and increased 2026 guidance, with ARCALYST showing strong market expansion and significant untapped potential. Pipeline assets KPL-387 and KPL-1161 are advancing, supported by robust clinical data and strategic focus on innovation, patient access, and long-term value.
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual ...
Kiniksa Pharmaceuticals International, Transcript: Canaccord Genuity's 46th Annual Growth Conference
ARCALYST continues to drive strong revenue growth and market penetration in recurrent pericarditis, with patients typically remaining on therapy for a median of three years. The company is advancing its pipeline with KPL-387 in phase III and expanding outreach through targeted education and DTC campaigns.
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th An...
Kiniksa price target raised to $90 from $75 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Kiniksa (KNSA) to $90 from $75 and keeps a Buy rating on the shares. Kiniksa delivered another beat-and-raise quarter,…
Kiniksa price target raised to $99 from $72 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $99 from $72 and keeps an Outperform rating on the shares. The firm notes the company reported positive recurrent pericarditis…
Kiniksa price target raised to $107 from $72 at JPMorgan
JPMorgan raised the firm’s price target on Kiniksa (KNSA) to $107 from $72 and keeps an Overweight rating on the shares.
Kiniksa price target raised to $98 from $64 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Kiniksa (KNSA) to $98 from $64 and keeps a Buy rating on the shares. The firm updated its model following…
Kiniksa price target raised to $100 from $60 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $100 from $60 and keeps a Buy rating on the shares. The firm views the company’s Q2…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q2 2026
Q2 2026 saw ARCALYST revenue surge 55% year-over-year to $243.6 million, driving a guidance raise to $980–995 million for the year. The pivotal phase III trial for KPL-387 began enrollment, supported by strong phase II data, while cash reserves grew to $525.9 million.
Kiniksa Pharmaceuticals International, Earnings release: Q2 2026
Kiniksa Pharmaceuticals International, released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Kiniksa Pharmaceuticals International, Slides: Q2 2026
Kiniksa Pharmaceuticals International, has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Kiniksa Pharmaceuticals International, Quarterly report: Q2 2026
Kiniksa Pharmaceuticals International, has published its Q2 2026 quarterly earnings report on July 28, 2026.
Kiniksa reports Q2 EPS 30c, consensus 28c
Reports Q2 revenue $243.6M, consensus $226.46M. “In the second quarter, Kiniksa (KNSA) continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis, which led to a…
Kiniksa raises FY26 revenue view to $980M-$995M from $930M-$945M
Consensus $940.13M. The company said, “Kiniksa (KNSA) expects 2026 ARCALYST net product revenue of between $980 million and $995 million, compared to prior guidance of between $930 million and $945…
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-...
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:...
Kiniksa price target raised to $75 from $60 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Kiniksa (KNSA) to $75 from $60 and keeps a Buy rating on the shares. Biotech has outperformed the broader…
Kiniksa price target raised to $74 from $57 at Wells Fargo
Wells Fargo raised the firm’s price target on Kiniksa (KNSA) to $74 from $57 and keeps an Overweight rating on the shares. Arcalyst revenue expectations appear achievable, but given the…
Kiniksa price target raised to $72 from $59 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $72 from $59 and keeps an Outperform rating on the shares. Arcalyst heads into Q2 earnings with continued commercial momentum…
Kiniksa Pharmaceuticals International, Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong commercial growth and expanded guidance for ARCALYST are supported by increasing prescriber adoption and a shift to chronic disease management. Pipeline assets KPL-387 and KPL-1161 are advancing, with key clinical milestones expected in 2024, and the company remains financially robust and focused on innovation.
Kiniksa Pharmaceuticals International, Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth led to raised 2026 revenue guidance for ARCALYST, with expanding physician adoption and ongoing efforts to increase patient awareness. Pipeline progress includes KPL-387 phase II data expected in H2 and KPL-1161 entering phase I by year-end. Cash reserves remain robust at $468 million.
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferen...